{"title": "Coronavirus disease-19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea", "doi": "10.1101/2020.03.15.20036350", "citation_id": "2020.03.15.20036350v1", "date": "2020-03-18", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.15.20036350", "abstract": "<p>Between January 24 and March 10, of a total of 2,370 individuals who had contacted the first 30 cases of COVID19, 13 were found to have COVID19, resulting secondary attack rate of 0.55% (95% CI 0.31 to 0.96). Of 119 household contacts, 9 had infections resulting secondary attack rate of 7.56 (95% CI 3.73 to 14.26).</p>", "twitter_description": "Between January 24 and March 10, of a total of 2,370 individuals who had contacted the first 30 cases of COVID19, 13 were found to have COVID19, resulting secondary attack rate of 0.55% (95% CI 0.31 to 0.96). Of 119 household contacts, 9 had infections resulting secondary attack rate of 7.56 (95% CI 3.73 to 14.26).\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNone exist\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nEpidemiologic investigation files from Korea CDC", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036350v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036350v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036350v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/18/2020.03.15.20036350.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.15.20036350v1", "access_rights": "restricted", "authors": ["Korea Centers for Disease Control and Prevention COVID-19 National Emergency Response Center", "Young June Choe"]}